ALEXION PHARMACEUTICALS, INC. Insider Trading for June 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ALEXION PHARMACEUTICALS, INC. for June 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 19 2017 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Buy | P | 116.72 | 10,000 | 1,167,200 | 38,725 | 28.7 K to 38.7 K (+34.81 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Buy | P | 117.10 | 2,000 | 234,200 | 6,333 | 4.3 K to 6.3 K (+46.16 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | PARVEN ALVIN S | Director | Sell | S | 116.78 | 835 | 97,511 | 7,568 | 8.4 K to 7.6 K (-9.94 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.95 | 22,560 | 2,660,914 | 7,317,906 | 7.3 M to 7.3 M (+0.31 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.95 | 2,564 | 302,419 | 647,367 | 644.8 K to 647.4 K (+0.40 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.51 | 197,126 | 23,163,488 | 7,295,346 | 7.1 M to 7.3 M (+2.78 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.51 | 22,399 | 2,632,017 | 644,803 | 622.4 K to 644.8 K (+3.60 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.22 | 32,172 | 3,771,228 | 7,098,220 | 7.1 M to 7.1 M (+0.46 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.22 | 3,656 | 428,559 | 622,404 | 618.7 K to 622.4 K (+0.59 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.01 | 65,264 | 7,636,802 | 7,066,048 | 7 M to 7.1 M (+0.93 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 117.01 | 7,416 | 867,776 | 618,748 | 611.3 K to 618.7 K (+1.21 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.96 | 898 | 105,030 | 7,000,784 | 7 M to 7 M (+0.01 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.96 | 102 | 11,930 | 611,332 | 611.2 K to 611.3 K (+0.02 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.71 | 31,974 | 3,731,542 | 6,999,886 | 7 M to 7 M (+0.46 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.71 | 3,634 | 424,108 | 611,230 | 607.6 K to 611.2 K (+0.60 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.37 | 12,726 | 1,480,897 | 6,967,912 | 7 M to 7 M (+0.18 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.37 | 1,446 | 168,268 | 607,596 | 606.2 K to 607.6 K (+0.24 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.37 | 385,774 | 44,891,517 | 6,955,186 | 6.6 M to 7 M (+5.87 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.37 | 43,835 | 5,100,965 | 606,150 | 562.3 K to 606.2 K (+7.80 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.18 | 1,976 | 229,562 | 6,569,412 | 6.6 M to 6.6 M (+0.03 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 116.18 | 224 | 26,023 | 562,315 | 562.1 K to 562.3 K (+0.04 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.77 | 169,897 | 19,668,568 | 6,567,436 | 6.4 M to 6.6 M (+2.66 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.77 | 19,305 | 2,234,894 | 562,091 | 542.8 K to 562.1 K (+3.56 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.71 | 207,814 | 24,046,636 | 6,397,539 | 6.2 M to 6.4 M (+3.36 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.71 | 23,614 | 2,732,430 | 542,786 | 519.2 K to 542.8 K (+4.55 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.06 | 18,678 | 2,149,048 | 6,189,725 | 6.2 M to 6.2 M (+0.30 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 115.06 | 2,122 | 244,152 | 519,172 | 517.1 K to 519.2 K (+0.41 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 114.33 | 64,455 | 7,369,301 | 6,171,047 | 6.1 M to 6.2 M (+1.06 %) |
Jun 16 2017 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 114.33 | 7,324 | 837,371 | 517,050 | 509.7 K to 517.1 K (+1.44 %) |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Option Exercise | A | 100.14 | 21,750 | 2,178,045 | 21,750 | |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Grant | A | 0.00 | 14,719 | 0 | 14,719 | 0 to 14.7 K |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Option Exercise | A | 100.14 | 25,165 | 2,520,023 | 25,165 | |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Grant | A | 0.00 | 12,582 | 0 | 12,582 | 0 to 12.6 K |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | LAW ANNE-MARIE | EVP and CHRO | Grant | A | 0.00 | 22,968 | 0 | 0 | -22,968 to 0 (-100.00 %) |
Jun 09 2017 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 24,965 | 0 | 24,965 | 0 to 25 K |